Cite

    Hamlin, P., Farber, C., Fenske, T., Khatcheressian, J., Miller, C., Munoz, J., Patel, M., Schreeder, M., Smith, S., Stevens, D., Pandey, A., Birrell, M., Leeds, J., Wang, Y., Coffey, G., & Curnutte, J. (n.d.). tHE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN a PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES. Hematological oncology, 35, 74. http://access.bl.uk/ark:/81055/vdc_100047473605.0x00002c